Neratinib + fulvestrant + trastuzumab for hormone-receptor positive, HER2-negative, HER2-mutant metastatic breast cancer: outcom
![Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection | Fierce Biotech Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2017-04/fda1.jpg?VersionId=ND3YtGrhn2xQdkzOr_wA9a3FAZW6PDXo)
Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection | Fierce Biotech
![Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile](https://res.cloudinary.com/crunchbase-production/image/upload/c_thumb,h_256,w_256,f_auto,g_faces,z_0.7,q_auto:eco,dpr_1/v1498388026/lvjklczpmuxg486pm7q6.jpg)
Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
![CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire](https://mms.businesswire.com/media/20210225006284/en/861643/23/01_CANbridge_Logo_1.18_highres.jpg)